Back to Search

RASolute 302: a Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

  • Protocol Number: 202409211
  • Principal Investigator: Lim, Kian-Huat
  • Cancer Types: Gastrointestinal

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.

Protocol Interventions

Drug: Gemcitabine, Drug: nab-paclitaxel, Drug: Irinotecan, Drug: Liposomal irinotecan, Drug: 5-fluorouracil, Drug: leucovorin, Drug: Oxaliplatin